Collecting Real World Evidence to improve outcomes of early-relapse multiple myeloma patients in Europe
The landscape of multiple myeloma treatment is rapidly evolving, yet significant challenges remain—especially for patients who relapse early after exposure to the latest frontline therapies.
We are launching a Call for Data Partners to collect and harmonize data in multiple myeloma to evaluate the outcomes of integrating novel treatment strategies after first relapse
Data will be used to:
- Leverage the understanding of treatment effectiveness,
- Showcase the extent of patients’ unmet needs, and
- Generate evidence supporting that the integration of novel treatment strategies after the first relapse will improve patient outcomes and drug resistance, which may prevent the poor outcomes associated with triple-class exposure
Join us as a Data Partner: send your Expression of Interest
If you manage a registry, database, or have access to real-world data of patients with MM, we want to hear from you! Together, we can generate the evidence needed to transform care for this difficult-to-treat population.
Benefits for Data Partners
- Access to the resulting database.
- Possibility to submit research questions using data on the HARMONY Platform.
- Access to dashboards to facilitate data visualization.
- Authorship rights in any publication resulting from the use of your data.
- Networking opportunities.
- Potential funding opportunities.
Fill out this form if you want to collaborate and receive further information
Why this matters
Multiple myeloma (MM) treatment is evolving with the introduction of novel therapies and their earlier integration into standard care. In the initial treatment phase, novel combinations, particularly quadruplet regimens including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, have become standard for both transplant-ineligible and transplant-eligible patients, leading to significant improvements in progression-free survival (PFS) and overall survival (OS). Many of these treatments require ongoing use, and patients often become refractory at the time of relapse or when the disease progresses.
Current guidelines indicate that two major patient groups predominate at first relapse, requiring the initiation of a second-line therapy: those refractory to lenalidomide and those refractory to both lenalidomide and anti-CD38 monoclonal antibodies. This situation limits treatment options, notably for patients who relapse early, which is within 12 to 18 months of starting therapy. These patients are considered high-risk, and there is a critical need for more research and real-world data on treating these difficult-to-treat populations and to prevent the poor outcomes associated with triple-class exposure.
Background
The HARMONY Alliance Foundation is a globally focused non-profit organization, established in Spain and built upon the achievements of two EU-funded IHI initiatives of HARMONY and HARMONY PLUS. The strategic focus of the foundation lies in using multi-source data and advanced analytics to speed up the development of therapies for patients with haematological malignancies.
For more than 8 years, the HARMONY Platform has powered high-impact research by providing structured, secure access to real-world data — supporting collaboration, insight generation, and better outcomes. We are now expanding our datasets and would like to invite you to share data reflecting recent treatments. If you are interested in contributing your data to the largest GDPR compliant data repository in haematological malignancies in the EU, and being part of a collaborative effort to move the field in the shortest time possible, please send your Expression of Interest.
Do you have any questions or suggestions?
Contact us and help shape the future of multiple myeloma treatment.